BÜHLMANN GanglioCombi® MAG ELISA is the only commercially available multiparametric IVD ELISA for clinically relevant neural antibodies, investigating anti-ganglioside antibodies and anti-MAG (myelin-associated glycoproteins) antibodies in the same approach. Three enzyme labels (IgG/IgM mix, IgG and IgM) allow for cost- and time effective algorithms including testing in 2 steps: (1st) initial screening for antibodies with the IgM/IgG mix followed by (2nd) re-testing of positive samples with IgG- and IgM-enzyme label to identify the underlying pathology.
The anti-MAG Antibodies ELISA by BÜHLMANN is the only IVD test based on human brain antigen and is the acknowledged gold standard to reliably quantify anti-MAG antibodies of IgM isotype in immune-mediated demyelinating neuropathies. The anti-MAG Antibodies ELISA may be used as stand-alone test or in combination with BÜHLMANN GanglioCombi® MAG ELISA to confirm auto-antibodies against MAG.
The anti-SGPG Antibodies ELISA is the only CE marked assay for IVD worldwide, determining anti-SGPG antibodies of IgM isotype. A combined use together with the anti-MAG Antibodies ELISA enhances the chance to detect all IgM-related neuropathies.
GanglioCombi™ Light ELISA combines on one microplate the three most relevant and frequent gangliosides, GD1b, GQ1b and GM1. The kit contains 3 enzyme labels: IgG/IgM mix, IgG and IgM.
Anti-GM1 Antibodies ELISA allows individual testing of anti-GM1 antibodies of the IgG and/or the IgM isotype. While IgG antibodies are related to Guillain-Barré Syndrome (GBS), IgM antibodies are found in multifocal neuropathy (MMN) and lower motor neuron disease (LMND).